These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 37634528

  • 1. Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
    Venturella R, Rechberger T, Zatik J, Wagman RB, Zhu E, Rakov VG, Petraglia F.
    Gynecol Endocrinol; 2023 Aug 17; 39(1):2249107. PubMed ID: 37634528
    [Abstract] [Full Text] [Related]

  • 2. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A, Venturella R, Arjona Ferreira JC, Li Y, Soulban G, Wagman RB, Lukes AS.
    Am J Obstet Gynecol; 2023 Dec 17; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA, Lukes AS, Venturella R, Li Y, Hunsche E, Wagman RB, Al-Hendy A.
    Am J Obstet Gynecol; 2023 Mar 17; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA.
    N Engl J Med; 2021 Feb 18; 384(7):630-642. PubMed ID: 33596357
    [Abstract] [Full Text] [Related]

  • 6. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA.
    Obstet Gynecol; 2022 Dec 01; 140(6):920-930. PubMed ID: 36357960
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline.
    Venturella R, Lukes AS, Wu R, McLean R, Rakov VG, Al-Hendy A.
    Int J Gynaecol Obstet; 2024 May 01; 165(2):431-441. PubMed ID: 38576220
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA, Diamond MP, Williams ARW, Carr BR, Myers ER, Feldman RA, Elger W, Mattia-Goldberg C, Schwefel BM, Chwalisz K.
    Hum Reprod; 2019 Apr 01; 34(4):623-634. PubMed ID: 30865281
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A, Lukes AS, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA.
    J Comp Eff Res; 2023 Aug 01; 12(8):e230069. PubMed ID: 37477173
    [Abstract] [Full Text] [Related]

  • 14. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary.
    Stewart EA, Lukes AS, Venturella R, Li Y, Hunsche E, Wagman RB, Al-Hendy A.
    J Comp Eff Res; 2024 Aug 01; 13(8):e230194. PubMed ID: 38934918
    [Abstract] [Full Text] [Related]

  • 15. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, Schlaff WD, Puscheck EE, Wang A, Gillispie V, Hurtado S, Muneyyirci-Delale O, Archer DF, Carr BR, Simon JA, Stewart EA.
    Am J Obstet Gynecol; 2021 Jan 01; 224(1):72.e1-72.e50. PubMed ID: 32702363
    [Abstract] [Full Text] [Related]

  • 16. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A, Whitaker L, Chow TL, Sobel ML.
    Cochrane Database Syst Rev; 2017 Apr 26; 4(4):CD010770. PubMed ID: 28444736
    [Abstract] [Full Text] [Related]

  • 17. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y, Enya K, Kudou K, Hoshiai H.
    Fertil Steril; 2019 Nov 26; 112(5):922-929.e2. PubMed ID: 31594635
    [Abstract] [Full Text] [Related]

  • 18. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
    Arjona Ferreira JC, Migoya E.
    F S Rep; 2023 Jun 26; 4(2 Suppl):73-82. PubMed ID: 37223761
    [Abstract] [Full Text] [Related]

  • 19. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H.
    Obstet Gynecol; 2019 Mar 26; 133(3):423-433. PubMed ID: 30741797
    [Abstract] [Full Text] [Related]

  • 20. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y, Mathur V, Warsi QA, Wagman RB, Johnson NP.
    Lancet; 2022 Jun 18; 399(10343):2267-2279. PubMed ID: 35717987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.